LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments

March 21, 2024

https://www.globenewswire.com/news-release/2024/03/21/2850210/0/en/LIXTE-Provides-Update-on-Progress-with-LB-100-as-a-PP2A-Inhibitor-to-Enhance-Chemotherapy-and-Immunotherapy-Cancer-Treatments.html

— Three Clinical Trials Currently Underway for Treating Ovarian, Lung and Sarcoma Cancers —

PASADENA, Calif., March 21, 2024 (GLOBE NEWSWIRE) — LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq:LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today provided an update on the Company’s progress with its proprietary compound, LB-100.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.